CDKL2 Clinical Trial

Over the past several years, families and clinicians have been searching for better ways to manage the severe and often life-threatening epilepsy associated with CDKL5 Deficiency Disorder. While the biology of CDKL5 is complex and still being studied, research has shown that related pathways in the brain may offer alternative ways to support children affected by this condition. One such pathway involves CDKL2, a closely related gene that shares overlapping functions with CDKL5 and may help compensate when CDKL5 activity is reduced or impaired.

In India, a clinician-led clinical trial is currently underway at Rainbow Children’s Hospital, Hyderabad, evaluating a repurposed and well-studied medication as an adjunct treatment for children with CDKL5. Instead of directly targeting the CDKL5 gene, this approach focuses on CDKL2-related pathways, informed by prior experience in treating difficult-to-control epilepsies. Early clinical observations have suggested meaningful reductions in seizure burden, along with improvements in alertness and day-to-day functioning in some children. This treatment is not a cure, but it may offer an important way to improve disease management and quality of life.

The trial is being led by Dr. Lokesh Lingappa and Dr. Prasanthi Aripirala, both experienced pediatric neurologists. Their work represents an important step toward generating structured clinical evidence for families affected by CDKL5 in South Asia. By carefully studying safety, feasibility, and early signs of benefit, this effort contributes to the broader global goal of identifying practical and accessible treatment options for children living with CDKL5 Deficiency Disorder.